ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

Carol Aghajanian, MD
Published: Monday, Sep 16, 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

The oncology community would like to see a gold standard of improved overall survival or at least a good way to measure clinical benefit, Aghajanian says. Patients with ovarian cancer live for a long time, receive multiple lines of therapy, and often cross over, in a sense, to receive therapies in the same class.

These factors make it difficult to measure overall survival.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

The oncology community would like to see a gold standard of improved overall survival or at least a good way to measure clinical benefit, Aghajanian says. Patients with ovarian cancer live for a long time, receive multiple lines of therapy, and often cross over, in a sense, to receive therapies in the same class.

These factors make it difficult to measure overall survival.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x